{
    "root": "620f749d-59d2-46fb-befa-7a1356bff383",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Lorbrena",
    "value": "20250501",
    "ingredients": [
        {
            "name": "LORLATINIB",
            "code": "OSP71S83EU"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        }
    ],
    "indications": "LORBRENA® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.",
    "contraindications": "Recommended dosage: 100 mg orally once daily. ( 2.2 ) Severe Renal Impairment: 75 mg orally once daily. ( 2.8 , 8.7 , 12.3 )",
    "warningsAndPrecautions": "Table 11 describes the available strengths and package configurations for LORBRENA:\n                  \n                     Table 11 \tLORBRENA Tablets\n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              Package Configuration\n                           \n                           \n                              Strength\n                              \n                               (mg)\n                           \n                           \n                              NDC\n                           \n                           \n                              Description\n                           \n                        \n                     \n                     \n                        \n                           \n                              30 count bottle with a child-resistant closure\n                           \n                           \n                              25\n                           \n                           \n                              0069-0227-01\n                           \n                           \n                              8 mm round, tan, immediate release film-coated, debossed with \"Pfizer\" on one side and \"25\" and \"LLN\" on the other side\n                           \n                        \n                        \n                           \n                              120 count bottle with a child-resistant closure\n                           \n                           \n                              25\n                           \n                           \n                              0069-0227-03\n                           \n                           \n                              8 mm round, tan, immediate release film-coated, debossed with “Pfizer” on one side and “25” and “LLN” on the other side\n                           \n                        \n                        \n                           \n                              30 count bottle with a child-resistant closure\n                           \n                           \n                              100\n                           \n                           \n                              0069-0231-01\n                           \n                           \n                              8.5 mm × 17 mm oval, lavender, immediate release, film-coated, debossed with \"Pfizer\" on one side and \"LLN 100\" on the other side",
    "adverseReactions": "LORBRENA is contraindicated in patients taking strong CYP3A inducers, due to the potential for serious hepatotoxicity [see Warnings and Precautions (5.1)]."
}